Prevention of cisplatin‐induced hearing loss in children: Informing the design of future clinical trials

Cisplatin is an essential chemotherapeutic agent in the treatment of many pediatric cancers. Unfortunately, cisplatin‐induced hearing loss (CIHL) is a common, clinically significant side effect with life‐long ramifications, particularly for young children. ACCL05C1 and ACCL0431 are two recently comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Minasian, Lori M., Frazier, A. Lindsay, Sung, Lillian, O’Mara, Ann, Kelaghan, Joseph, Chang, Kay W., Krailo, Mark, Pollock, Brad H., Reaman, Gregory, Freyer, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051159/
https://www.ncbi.nlm.nih.gov/pubmed/29846043
http://dx.doi.org/10.1002/cam4.1563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051159/
https://www.ncbi.nlm.nih.gov/pubmed/29846043
http://dx.doi.org/10.1002/cam4.1563

Ejemplares similares